Notable
KID-BID · Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets · Sickle Cell Disease
Primary and study completion pushed from Feb 2027 to Feb 2028
TheraviaPhase 2 NCT06578507 Registry history of NCT06578507 on ClinicalTrials.gov (opens the registry)